Navigation Links
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
Date:2/10/2009

HAYWARD, Calif., Feb. 10 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a Phase IIa clinical trial for AR9281, an orally- administered soluble epoxide hydrolase (s-EH) inhibitor being developed for the treatment of type 2 diabetes. S-EH is an enzyme involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders.

"Our AR9281 Phase II clinical trial program breaks new ground in two key areas. This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension," said James Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "AR9281 has demonstrated an excellent safety profile and activity in multiple animal models of type 2 diabetes, and has the advantage of inhibiting a novel drug target that differentiates it from currently marketed diabetes medications. With this promising drug profile, AR9281 has the potential to provide safe and effective therapy for patients with type 2 diabetes either as monotherapy or in combination with existing treatment regimens."

The Phase IIa multicenter, double-blind, placebo-controlled study will enroll 150 pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All patients enrolled in the study will be treatment-naïve for type 2 diabetes medications. The trial will evaluate two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice-a-day dosing. Each patient will receive 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.

"AR9281 operates within the third branch of the arachidonic acid pathway and represents a potentially more specific and selective approach to intervene in metabolic and inflammatory diseases. The first two branches of this critical regulatory pathway have been targeted by several commercially successful marketed anti-inflammatory drugs including Aspirin(R) (acetylsalicylic acid), Motrin(R) (ibuprofen), Singulair(R) (Montelukast) and Celebrex(R) (celecoxib). We designed our Phase IIa trial to further validate the role of s-EH in the pathophysiology of disease and to lay the groundwork for further exploration of s-EH inhibition in treating a broad range of serious diseases including type 2 diabetes, hypertension and inflammatory disorders," commented Randall Whitcomb, M.D., Chief Medical Officer of Arete.

The results of a Phase I clinical program consisting of two double-blind, placebo-controlled studies demonstrated that AR9281 was safe and well tolerated in healthy volunteers. The studies met all safety, tolerability, pharmacokinetic and pharmacodynamic endpoints. In addition, AR9281 has shown favorable results in various published and proprietary in vitro and in vivo assays for potency, selectivity, efficacy, ADME, toxicity and safety.

About Arete Therapeutics Inc.

Arete Therapeutics is a privately-held biotechnology company dedicated to the discovery and development of novel drugs to treat type 2 diabetes, hypertension and inflammatory disorders. It is the world's leading company focused on s-EH, an important enzyme for the metabolism of arachidonic acid that plays an essential role in metabolic, inflammatory and cardiovascular physiology. The Company was founded by Dr. Bruce Hammock, a Professor at the University of California, Davis, who discovered s-EH. The Company has raised a total of over $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, Burrill & Company and Altitude Life Science Ventures. For more information on Arete Therapeutics, please visit www.aretetherapeutics.com.


'/>"/>
SOURCE Arete Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
2. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
3. Arete Therapeutics Appoints Donald Santel to Board of Directors
4. CareTech Solutions Service Desk Equals Help Desk Plus
5. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community
6. CareTech Solutions Named Best in KLAS for Extensive IT Outsourcing Services
7. EnovateIT Partners with CareTech Solutions to Create a Custom Product for Crittenton Hospital Medical Center, One of the Nation's Most Wired Hospitals
8. Prime Therapeutics Receives TIPPS Certification
9. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
10. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
11. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... VA (PRWEB) , ... May 26, 2017 , ... ... pleased to announce a new educational seminar to focus on current legislative activity ... News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will continue ...
(Date:5/26/2017)... ... 2017 , ... Boar’s Head Brand®, one of the nation’s ... entertaining that are sure to satisfy your guests’ flavor cravings, while adding delicious ... featured in these refreshingly balanced recipes are packed with flavor, creating the perfect ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: ... the creation of published author Laura Weigel Douglas, an avid reader who lives in ... house that sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: the ... others. “Cactus Jack: Against All Odds” is the creation of published author, Walter ... is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane have ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
(Date:5/12/2017)... Canada joint tech company Laughing Face has developed ... and features a powerful disinfection process. The company has ... and sanitizes women,s panties or babies, cloth diapers in 25 minutes. ... Laughing ... external water inlet. ...
(Date:5/10/2017)... , May 10, 2017 Radiology has ... unfortunately its costs have also spiraled to the number ... sent to radiology than ever before as the most ... For a patient with lower back pain an MRI ... anatomical reason for pain, resulting in entirely different treatment ...
Breaking Medicine Technology: